Loading [MathJax]/jax/output/SVG/jax.js
Review Topical Sections

Dietary influence on estrogens and cytokines in breast cancer

  • Breast cancer affects one out of eight women in their lifetime. Many factors contribute to the development of breast cancer, such as hereditary mutations and lifetime exposure to environmental factors, including estrogen. In addition, overweight and obesity, especially with increased waist circumference, are known to be associated with breast cancer risk. This review will summarize our understanding of the effect of diet on breast cancer incidence and progression. Since some inflammatory cytokines that are changed by a high-fat diet are known to promote the growth of breast cancer cells, these cytokines may serve as biomarkers to monitor the dietary influence for women at high risk of breast cancer and as future therapeutic targets for breast cancer treatment.

    Citation: Xin Nian, Yasuhiro Nagai, Cameron Jeffers, Kara N. Maxwell, Hongtao Zhang. Dietary influence on estrogens and cytokines in breast cancer[J]. AIMS Molecular Science, 2017, 4(3): 252-270. doi: 10.3934/molsci.2017.3.252

    Related Papers:

    [1] Edil D. Molina, Paul Bosch, José M. Sigarreta, Eva Tourís . On the variable inverse sum deg index. Mathematical Biosciences and Engineering, 2023, 20(5): 8800-8813. doi: 10.3934/mbe.2023387
    [2] Wanlin Zhu, Minglei Fang, Xianya Geng . Enumeration of the Gutman and Schultz indices in the random polygonal chains. Mathematical Biosciences and Engineering, 2022, 19(11): 10826-10845. doi: 10.3934/mbe.2022506
    [3] Xinmei Liu, Xinfeng Liang, Xianya Geng . Expected Value of Multiplicative Degree-Kirchhoff Index in Random Polygonal Chains. Mathematical Biosciences and Engineering, 2023, 20(1): 707-719. doi: 10.3934/mbe.2023032
    [4] Saylé C. Sigarreta, Saylí M. Sigarreta, Hugo Cruz-Suárez . On degree–based topological indices of random polyomino chains. Mathematical Biosciences and Engineering, 2022, 19(9): 8760-8773. doi: 10.3934/mbe.2022406
    [5] Qi Wang, Lifang Huang, Kunwen Wen, Jianshe Yu . The mean and noise of stochastic gene transcription with cell division. Mathematical Biosciences and Engineering, 2018, 15(5): 1255-1270. doi: 10.3934/mbe.2018058
    [6] V. R. Kulli, J. A. Méndez-Bermúdez, José M. Rodríguez, José M. Sigarreta . Revan Sombor indices: Analytical and statistical study. Mathematical Biosciences and Engineering, 2023, 20(2): 1801-1819. doi: 10.3934/mbe.2023082
    [7] Ricai Luo, Khadija Dawood, Muhammad Kamran Jamil, Muhammad Azeem . Some new results on the face index of certain polycyclic chemical networks. Mathematical Biosciences and Engineering, 2023, 20(5): 8031-8048. doi: 10.3934/mbe.2023348
    [8] Xiujun Zhang, H. G. Govardhana Reddy, Arcot Usha, M. C. Shanmukha, Mohammad Reza Farahani, Mehdi Alaeiyan . A study on anti-malaria drugs using degree-based topological indices through QSPR analysis. Mathematical Biosciences and Engineering, 2023, 20(2): 3594-3609. doi: 10.3934/mbe.2023167
    [9] Mert Sinan Oz, Roberto Cruz, Juan Rada . Computation method of the Hosoya index of primitive coronoid systems. Mathematical Biosciences and Engineering, 2022, 19(10): 9842-9852. doi: 10.3934/mbe.2022458
    [10] Peng Gu, Dongrong Yang, Jin Zhu, Minhao Zhang, Xiaoliang He . Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis. Mathematical Biosciences and Engineering, 2021, 18(4): 3180-3196. doi: 10.3934/mbe.2021158
  • Breast cancer affects one out of eight women in their lifetime. Many factors contribute to the development of breast cancer, such as hereditary mutations and lifetime exposure to environmental factors, including estrogen. In addition, overweight and obesity, especially with increased waist circumference, are known to be associated with breast cancer risk. This review will summarize our understanding of the effect of diet on breast cancer incidence and progression. Since some inflammatory cytokines that are changed by a high-fat diet are known to promote the growth of breast cancer cells, these cytokines may serve as biomarkers to monitor the dietary influence for women at high risk of breast cancer and as future therapeutic targets for breast cancer treatment.


    Plant-herbivore interactions have been studied previously by a huge number of investigators including mathematicians and ecologists by using differential equation models and theories in dynamical systems. One of the most commonly use differential equations used the traditional Holling Type II functional response, which assumes that the growth rate of herbivore is a monotonically increasing function of plant density. However, this will not be reasonable if the chemical defense of plants is considered, in which case the negative effect of plant toxin on herbivore can lead to a decrease in the growth rate when the plant density is high. To explore the impact of plant toxicity on the dynamics of plant-herbivore interactions, models that include a toxin-determined functional response are proposed. The toxin-determined functional response is a modification of the traditional Holling Type II response by including the negative effect of toxin on herbivore growth, which can overwhelm the positive effect of biomass ingestion at sufficiently high plant toxicant concentrations.

    In this paper, we consider the following system of plant-herbivore interactions with toxin-determined functional responses:

    {Uτ=D1ΔU+AU(1UK)eU1+heU(1eBU1+heU)V,(x,τ)Ω×(0,),Vτ=D2ΔVEV+eCU1+heU(1eBU1+heU)V,(x,τ)Ω×(0,),νU=νV=0,(x,τ)Ω×(0,),U(x,0)=U0(x)0,V(x,0)=V0(x)0,xΩ, (1.1)

    where Ω is a bounded open domain in RN (N1) with a smooth boundary Ω; U and V are the densities of the plant and herbivore for (x,τ)Ω×(0,) respectively; D1 and D2 stand for the diffusion rates of the plant (for seed dispersal) and the predator respectively. A and K are the intrinsic growth rate and carrying capacity of the plant species respectively; e is the rate of encounter per unit plant per herbivore, h is the average time required for handling one unit of plant biomass; C is the conversion rate of the consumed plant biomass into new herbivore biomass; E is the per capita death rate of the herbivore due to causes unrelated to plant toxicity. The term 1eBU/(1+heU), captures the negative toxin effects, where it is required that h/4<B<h.

    System (1.1) has been studied extensively by several authors, but most of the research focuses either on the corresponding ODEs system or on the PDEs system but concentrating on the traveling wave solutions. For example, Feng, Liu and DeAngelis [1] studied the stability of the equilibrium solutions and Hopf bifurcations of the ODEs system; Liu, Feng, Zhu and DeAngelis [2] further performed detailed bifurcation analysis of the ODEs system reveals a rich array of possible behaviors including cyclical dynamics through Hopf bifurcations and homoclinic bifurcation; Castillo-Chavez, Feng and Huang [3] studied the global dynamics of the corresponding ODEs system. They were able to find necessary and sufficient condition on the nonexistence of a closed orbit via the transformation of the model to a new equivalent system. The Poincare-Bendixson theorem was used to show that the existence of a unique interior equilibrium point guarantees its global asymptotical stability whenever it is locally asymptotically stable. Zhao, Feng, Zheng and Cen [4] studied the existence of limit cycles and homoclinic bifurcation in the ODEs. By using the theory of rotated vector fields and the extended planar termination principle, they showed the existence of limit cycles and homo-clinic loop. Li, Feng, Swihart, Bryant and Huntly [5] considered an ODE system of n plant species and one herbivore population, which exhibits a rich variety of complex dynamics including Hopf bifurcation and period-doubling bifurcations. Feng, Huang and DeAngelis [6] studied the reaction-diffusion models for plant-herbivore interactions with toxin-determined functional response with two plant species that have different levels of toxicity. It was shown that under suitable conditions, the system might have traveling wave solutions; More recently, Xiang, Wu and Wan [7] use the steady state bifurcation theory and Hopf bifurcation theory to study the existence of multiple bifurcations.

    In this paper, however, we shall limit our attention to the occurrence of steady state solutions bifurcating from the positive constant equilibrium solution by using the classical local and global steady state bifurcation theory in the sense of Crandall and Rabinowitz ([8,9]). By using the diffusion rate d2 of the predator as the main bifurcation parameter, we are able to show the existence of global bifurcating branches consisting of positive non-constant steady state solutions, that is., for any d2 larger than certain critical value, then the diffusive system will have at least a positive non-constant steady state solution. On the other hand, compared with the diffusion rate d1 of the plant, the diffusion rate d2 of the herbivore tend to be sufficiently large from practical point of view. Thus, for any fixed d1, the dynamics of the system for sufficient larger d2 will be of great concern. Note that one way to solve the steady states of (1.2) for the larger d2 case is to use the "shadow system"approach [10], which basically considers the limiting system when the diffusion rate d2 tends to infinity. The shadow system is presumably easier to analyze, and the wish is that properties of solutions to the shadow system reflect that of the solutions to the original system, at least for d2 sufficiently large. To a certain extent, this is true. From this point of view, the shadow system approach is the main advantage of our work compared with other existing literatures when we consider the case of d2 sufficiently large.

    Based on the aforementioned observations, we are to prove the existence of the positive non-constant steady state solutions of both original system and its limiting system-the shadow system. To make our discussions simpler, we introduce the following change of variables:

    t=τA,u=ehU,v=ehVC,d1=D1A,d2=D2A,k=Keh,m=ChA,θ=EA,γ=Bh.

    Then, we can reduce system (1.1) to the following dimensionless form

    {ut=d1Δu+u(1uk)mu1+u(1γu1+u)v,(x,t)Ω×(0,),vt=d2Δvθv+mu1+u(1γu1+u)v,(x,t)Ω×(0,),νu=νv=0,(x,t)Ω×(0,),u(x,0)=u0(x)0,v(x,0)=v0(x)0,xΩ, (1.2)

    where γ(1/4,1). System (1.2) is similar to the classical predator-prey system with Holling type-II functional responses where γ=0. (For more details, we refer to [11,12] and references therein). To facilitate the needs to perform our bifurcation analysis, without loss of generality, we treat only the simpler case when Ω:=(0,) for >0.

    The remaining parts of this paper are organized as follows. In Section 2, we consider the spatial patterns of the original system by performing detailed local and global steady state bifurcation to the original system; In Section 3, we study the spatial patterns of the shadow system (the limiting system when d2) by using the time-mapping methods; In Section 4, we end up our discussions by drawing some conclusions.

    In this section, we shall perform detailed global steady state bifurcation analysis to the system by using d2 as the bifurcation parameter. Without loss of generality, we shall limit our attention to the case of Ω=(0,) for >0. The steady state problem of system (1.1) is governed by the following elliptic equations:

    {d1Δu+u(1uk)mu1+u(1γu1+u)v=0,x(0,),d2Δvθv+mu1+u(1γu1+u)v=0,x(0,),νu=νv=0,x=0,. (2.1)

    One can check that: if 1/4<γ1/2 holds, then u1+u(1γu1+u) is increasing in u, while it is unimodal if 1/2<γ<1 holds, more precisely, if 0<u<1/(2γ1), it is increasing, while if u>1/(2γ1), it is decreasing.

    Clearly, if 14<γ12 and θm(0,k1+k(1γk1+k)) holds, then system (2.1) has a unique positive constant solution, denoted by (λ,vλ), satisfying 0<λ<k and

    λ1+λ(1γλ1+λ)=θm,vλ:=(kλ)(λ+1)2mk(1+(1γ)λ).

    Define X={(u,v):u,vC2[0,],u=v=0 onx=0,} and Y=L2(0,)×L2(0,) be the Hilbert space with the inner product

    (U1,U2)Y:=(u1,u2)L2(0,)+(v1,v2)L2(0,)

    for U1:=(u1,v1)Y,U2:=(u2,v2)Y. Define the mapping F:(0,)×XY by

    F(d2,u,v):=(d1u+u(1uk)mu1+u(1γu1+u)vd2vθv+mu1+u(1γu1+u)v).

    Clearly, for all d2>0, we have F(d2,λ,vλ)=0. The linearized operator evaluated at (λ,vλ) is given by

    L:=F(u,v)(d2,λ,vλ)=(d1Δ+σ1(λ)θσ2(λ)d2Δ),

    where Δ:=2x2 and

    σ1(λ):=λ(2(1γ)λ2+(kkγ3)λ+k+kγ1)k(1+(1γ)λ)(1+λ),σ2(λ):=(kλ)(1+(12γ)λ)k(1+λ)(1+(1γ)λ).

    By [7,10,12], the eigenvalues of L can be determined by the eigenvalues of Ln defined by

    Ln=(σ1(λ)d1τnθσ2(λ)d2τn),nN0:={0,1,2,}, (2.2)

    where τn is the eigenvalue of Δ on Ω subject to the homogenous Neumann boundary conditions satisfying 0=τ0<τ1<τ2<. The characteristic equation of Ln is given by

    ρ2Tn(λ)ρ+Dn(λ)=0, (2.3)

    where

    Tn(λ)=σ1(λ)(d1+d2)τn,Dn(λ):=d1d2τ2na11(λ)d2τn+θσ2(λ). (2.4)

    One can check that: if k1/(1+γ) holds, then for all λ(0,k), σ1(λ)<0; while if k>1/(1+μ) holds, then there exists a ˆλ(0,k), such that for any λ(0,ˆλ), σ1(λ)>0, σ1(ˆλ)=0, while for any λ(ˆλ,k), σ1(λ)<0.

    Then, if either k1/(1+γ) or k>1/(1+γ) but λ(ˆλ,k), we have σ1(λ)<0, indicating that Tn(λ)<0. Since σ2(λ)>0 for λ(0,k), we have Dn(λ)>0. Hence, (λ,vλ) is locally asymptotically stable in system (2.1).

    Now, we mainly consider the case when k>1/(1+γ) but λ(0,ˆλ), in which case σ1(λ)>0.

    Then, zero is an eigenvalue of Ln if and only if

    d2=d(n)2:=θσ2(λ)(σ1(λ)d1τn)τn,for some n>0such that τn<σ1(λ)/d1. (2.5)

    Defining d2=d(n)2, we have kerL=span{Φ}, with Φ=(1,κn)Tϕn, where ϕn is the eigenfunction Δ corresponding to τn, and κn=(σ1(λ)d1τn)/θ>0.

    Consider the adjoint operator of L:

    L:=(d1Δ+σ1(λ)σ2(λ)θd2Δ).

    Then, kerL=span{Φ}, with Φ=(1,κn)Tϕn, where κn=(d1τnσ1(λ))/σ2(λ)<0. Since rangeL=(kerL), the codimension of rangeL is the same as dimL=1. Thus, kerF(u,v)(d(n)2,λ,vλ) and Y/rangeF(u,v)(d(n)2,λ,vλ) are one-dimensional.

    Finally, we show that F(d2,(u,v))(d(n)2,λ,vλ)ΦrangeF(u,v)(d(n)2,λ,vλ). In fact, we have

    F(d2,(u,v))(d(n)2,λ,vλ)Φ=(000Δ)(1κn)ϕn=(0τnκnϕn)

    and (F(d2,(u,v))(d(n)2,λ,vλ)Φ,Φ)Y=(τnκnϕn,knϕn)L2=τnκnkn>0. Thus, we can conclude that F(d2,(u,v))(d(n)2,λ,vλ)ΦrangeF(u,v)(d(n)2,λ,vλ).

    So far, by Theorem 1.7 of [8], we have the following results on the local existence of the steady state bifurcation branches:

    Theorem 2.1. Suppose that 14<γ12, k>1/(1+γ), θm(0,k1+k(1γk1+k)), λ(0,ˆλ) and n is a positive integer such that τn<σ1(λ) and d(n)2d(m)2 for any integers mn. Then, (d(n)2,λ,vλ) is a steady state bifurcation point. More precisely, there exists a one-parameter family of non-constant positive solutions (d2(s),u(s)(x),v(s)(x)) of system (2.1) for |s| sufficiently small, where d2(s), u(s), v(s) are continuous functions, d2(0)=d(n)2, and u(s)=λ+sϕn+o(s), v(s)=vλ+sκnϕn+o(s), where κn=(σ1(λ)d1τn)/θ>0. The zero set of F consists of two curves (d2(s),u(s)(x),v(s)(x)) and (d2,λ,vλ) in a neighborhood of the bifurcation point (d(n)2,λ,vλ).

    Definition 2.2. ([13]) A component A of the set of the non-constant solution of system (2.1) is said to exist globally with respect to d2 if and only if ¯Proj(A) contains 0, where Proj stands for the projection operator from (0,+)×X to d2 space and the upper bar represents the closure operator in R.

    Next, we shall consider the existence of global steady state bifurcation branches.

    Theorem 2.3. Let C1 be the closure of the set of the non-constant solution of system (2.1) in (0,+)×X. Denote by Cd(n)2 the component in C1 to which (d(n)2,λ,vλ) belongs. Under the same assumptions of Theorem 2.1, the component Cd(n)2 exists globally with respect to d1.

    Proof. 1) We first argue that, if (u(x),v(x)) is a non-negative solution of (2.1), then, either (u,v) is one of (0,0) and (k,0), or for x¯Ω, (u(x),v(x)) is a non-constant positive solution such that 0<u(x)<k and 0<v(x)<k(d2+θd1)/(θd2). This can be obtained by slightly modifying the proof of Lemma 3.5 in [12].

    2) We are going to use Theorems 2.2 and 2.3 of [13] to prove our desired results. Before going, we would like to comment that our results (Theorem 2.3) are similar to but different from Theorem 2.2 of [13] since Theorems 2.2 and 2.3 of [13] chooses d1 as main bifurcation parameter (fixing d2), while ours chooses d2 as main bifurcation parameter (fixing d1).

    Following [13], we define the hyperbolic curves {Cn}n=1 in (0,+)×(0,+) by

    Cn:={(d1,d2)(0,+)×(0,+):d2=d(n)2:=θσ2(λ)(σ1(λ)d1τn)τn}.

    Let C1 be the closure of the set of the non-constant solution of system (2.1) in (0,+)×X. Denote by Cd(n)2 the component in C1 to which (d(n)2,λ,vλ) belongs.

    To study the existence of global steady state bifurcations, it means to consider how the local bifurcating branch behaves when d2 leaves the critical value d(n)2. By the Rabinowitz's standard global bifurcation theorem [9], the component in (0,+)×X which contains the local bifurcating branch exists globally in the sense that either there is no closed bounded set in the interior of (0,+)×X which contains the component, or else such a set must contain the bifurcation points other than (d(n)2,λ,vλ). We shall rule out the possibility of the latter case.

    For each fixed d1, we denote the countable set {d(n)2:(d1,d(n)2)n=1Cn{(d1,d2)CnCm:mn}} by Bd1.

    Since the non-constant positive solution of system (2.1) is bounded as shown in part 1, by the Rabinowitz's standard global bifurcation theorem, to prove the desired results, it sufficient to rule out the possibility that Cd(n)2 contains a finite subset P={d(n)2:(d(n)2,λ,vλ)Cd(n)2} of Bd1. Suppose otherwise. Following [13], define

    ¯q=max{q,there exists an elementd(q)2ofPsuch that(d(q)2,λ,vλ)Cd(n)2},

    and denote the value of d(q)2P which attains ¯q by d(¯q)2. Under the assumptions of Theorem 2.1, d(n)2d(m)2 for any integers mn. Thus, the bifurcation point (d1,d(¯q)2)C¯q is simple. By Remark 1.2 of [13], it follows that if (d1,d(¯q)2)C¯q, then (¯q2d1,¯q2d(¯q)2)C1. This implies that (¯q2d1,¯q2d(¯q)2)C1 is simple. In particular, by (2.3) of [13], we have

    T¯q(C(¯q2d(¯q)2)(1))Cd(n)2, (2.6)

    where T¯q (with ¯q any of the positive integer) is defined in the following way (See also (2.2) of [13]):

    T¯q(U0(x))={U0(¯q(xi¯q)),ifiis even,U0(¯q(1¯qx+i¯q)),ifiis odd, (2.7)

    where U0(x) is any smooth solution of (2.1) with (d1,d2)=(d1,d(n)2).

    Suppose that C(¯q2d(¯q)2)(1) exists globally (does not contain a bifurcation point different from (d(n)2,λ,vλ)), then T¯q(C(¯q2d(¯q))(1)2) also exists globally (does not contain a bifurcation point different from (d1,d(n)2), which is impossible since by (2.6), Cd(n)2 contains a finite subset P={d(n)2:(d(n)2,λ,vλ)Cd(n)2} of Bd1. A contradiction!

    Suppose that C(¯q2d(¯q)2)(1) does not exist globally, then it must contain a bifurcation point (d1,¯q2d(s)2) for some interger s2. However, this is also impossible since it contradicts the fact that ¯q is the maximum value of q, since by T¯q(C(¯q2d(¯q)2)(1)), we can obtain that Cd(n)2 must contain (d(¯q)s2,λ,vλ). Again, the contradiction occurs. Thus, the proof is completed.

    In this section, we shall consider the existence of non-constant positive steady state solution of the shadow system of the original system, say letting d2.

    Rewrite the second equation of system (2.1) in the following way:

    vxx+d12(mu1+u(1γu1+u)θ)v=0. (3.1)

    Since 0<u(x)<k and 0<v(x)<k(d2+θd1)/(θd2), then for fixed d1>0, as d2, we have 0u(x)k,0v(x)k/θ. Then, as d2, we have, Δv0. Therefore, vξ, where ξ is a constant satisfying 0ξk/θ.

    Thus, as d2, system (2.1) is reduced to the following limit system:

    {d1Δu+u(1uk)mu1+u(1γu1+u)ξ=0,x(0,),νu=0,x=0,,0(mu1+u(1γu1+u)θ)dx=0, (3.2)

    with 0u(x)k,0ξk/θ, γ(1/4,1). System (3.2) is called shadow system of (2.1).

    As in Theorem 2.1, we assume that 1/4<γ1/2 and θm(0,k1+k(1γk1+k)) hold so that system (3.2) has a unique positive constant solution, denoted by (λ,vλ).

    We claim that the set of increasing solutions will be able to characterizes all the solutions of (3.2). In fact,

    1) The set of increasing solutions can describe all the decreasing solutions of (3.2). Indeed, suppose that system (3.2) has an increasing solution u=u(x) in (0,), then we can check that u(x):=u(x) must be a decreasing solution of system (3.2); Thus, by using increasing solutions, we can construct decreasing solutions;

    2) The set of increasing solutions can describe all the solutions of (3.2) (not necessarily limited to the decreasing solutions). Indeed, suppose that system (3.2) has an increasing solution u=u(x) in (0,). Following Lemma 2.1 of [13], we define

    un(x)={u(n(xin)),ifiis even,u(n(n(xin))),ifiis odd,

    for i/nx(i+1)/n and 0in1, with n>2; In fact, un(x) is constructed by means of successive (n1)-times reflections of u(nx)(0x/n) at i/n(i=1,2,,n1). Since (3.2) is an autonomous system and un(x) is matched at i/n(i=1,2,,n1). Thus, one can check that un(x) is the solution of d1/n2Δu+u(1uk)mu1+u(1γu1+u)ξ=0. Since the purpose of the paper is to find the non-constant solution of d1/Δu+u(1uk)mu1+u(1γu1+u)ξ=0 for small d1 (See the conditions f(λ)>d1π22 in Theorem 3.3). Thus, if we are able to prove the existence of the increasing solution of (3.2) in (0,), we can construct other non-monotone solutions un(x) by using d1/n2 to replace d1;

    In the following, we shall only concentrate on the increasing solutions of system (3.2).

    We define

    f(u):=u(1uk)mu1+u(1γu1+u)ξ,andF(u):=u0f(s)ds, (3.3)

    and introduce the energy functional I(x):=d12(ux(x))2+F(u(x)). Then, I(x)=d1u(x)+f(u) in (0,). If u=u(x) is a non-constant increasing solution of (3.2), then I(x)0 in (0,) and F(u(x))<F(u(0))=F(u()), since u(0)=u()=0. In particular, F(u) must attain its local minimal value at a point in (u(0),u()).

    We rewrite f(u) as

    f(u)=mu1+u(1γu1+u)(p(u)ξ),where,p(u):=(ku)(u+1)2mk(1+(1γ)u). (3.4)

    Clearly, p(0)=1/m, p(+)=. We have the following results on the function p(u):

    Lemma 3.1. 1) Suppose that k1/(1+γ) holds. Then, p(u) is strictly decreasing in (0,) and there exists a unique u(0,), such that for any u(0,u), p(u)>0 for any u(0,u), while p(u)<0 for any u(u,). In particular, p(u) attains its local maximal value at u=0.

    2) Suppose that k>1/(1+γ) holds. Then, there exists u,u(0,), with u<u, such that for any u(0,u), p(u)>0 for any u(0,u), while p(u)<0 for any u(u,). In particular, p(u) attains its maximal value at u=u. Moreover, for any u(0,u), p(u)>0 for any u(0,u), while p(u)<0 for any u(u,).

    Proof. Note that

    p(u)=u+1km(1+(1γ)u)2(2(1γ)u2+(k(1γ)3)u+k(1+γ)1).

    Analyzing the properties of p(u), we can obtain the desired results.

    From (3.4) and Lemma 3.1, it follows that: if either k1/(1+γ) or k>1/(1+γ) but ξp(u) holds, F(u) will never its minimal value point in (0,). Therefore, system (3.2) will never have positive non-constant solutions. Thus, to expect non-constant positive solutions, we need to assume that k>1/(1+γ) and ξ(1/m,p(u)). In this case, by (3.4), f(u)=0 have two roots in (0,), denoted by u1,2(ξ), satisfying 0<u1(ξ)<u<u2(ξ)<u; And f(u)<0 for 0<u<u1(ξ) and u2(ξ)<u<+, while f(u)>0 for u1(ξ)<u<u2(ξ). Therefore, F(u) is decreasing in (0,u1(ξ))(u2(ξ),), and increasing in (u1(ξ),u2(ξ)). In particular, F(u) takes its local minimum value at u=u1(ξ). Define

    κ0(ξ):={0,ifF(0)F(u2(ξ)),κ(ξ),ifF(0)>F(u2(ξ)),

    where κ(ξ)(0,u1(ξ)), such that F(κ(ξ))=F(u2(ξ)). Then, for any u(0)(κ0(ξ),u1(ξ)), there exists a unique u0(ξ)(u1(ξ),u2(ξ)), such that F(u(0))=F(u0(ξ)).

    Since I(x)0, we have I(x)F(α), where we write u(0)=α and u()=β. Since u(x) is assumed to be positive, we have

    u(x)=1d12(F(α)F(u)),x(0,). (3.5)

    Integrating (3.5) from 0 to , by u(0)=α and u()=β, we have,

    =d1βαdu2(F(α)F(u)).

    Regarding in (3) as a function of α, we have the following results:

    Lemma 3.2. Suppose that 14<γ12, ξ(1/m,p(u)) and k>11+γ hold. Then, for any α(κ0(ξ),u1(ξ)), ddα<0.

    Proof. Step 1: Following [10], for a given number u(α,β), define u=ρ(s) by the relation

    F(ρ(s))F(u1(ξ))=s22,signs=sign(uu1(ξ))=sign(f(u)). (3.6)

    Differentiating the first equation of (3.6) with respect to s, we have f(ρ(s))ρ(s)=s. By the second equation of (3.6), we have ρ(s)>u1(ξ) for s>0, ρ(0)=0 and ρ(s)<u1(ξ) for s<0. This together with f(ρ(s))ρ(s)=s, implies that ρ(s)>0 for all s0, where we use the facts that f(u)>0 for u(u1(ξ),u2(ξ)) and f(u)<0 for u(κ0(ξ),u1(ξ)). Then, s=ρ1(u) is well defined and is strictly increasing in (α,β). By [10] (pages of 314–315), we have

    ρ(s)=2(F(u)F(u1(ξ)))|f(u)|,ρ(s)=f2(u)+2f(u)(F(u)F(u1(ξ)))f3(u), (3.7)

    and ρ(s)=ρ(s)f4(u)z(u), where

    z(u):=2f(u)f(u)(F(u)F(u1(ξ)))+3f(u)(f2(u)2f(u)(F(u)F(u1(ξ)))). (3.8)

    In particular, ρ(0)=1f(u1(ξ)) and

    ρ(0)=f(u1(ξ))3(f(u1(ξ)))2,ρ(0)=(5(f(u1(ξ)))23f(u1(ξ))f(u1(ξ)))12(f(u1(ξ)))7. (3.9)

    Step 2: Let ω>0 be given by

    12ω2=F(α)F(u1(ξ))>0,α(κ0(ξ),u1(ξ)), (3.10)

    which implies from (3.6) that 2(F(α)F(u))=ω2s2 and

    =d1ωωρ(s)dsω2s2=d1π0ρ(ωcost)dt, (3.11)

    where the last equality was obtained by making the change of variable s=ωcost, 0tπ. Regarding ω in (3.10) as a function of α in (κ0(ξ),u1(ξ)), by f(α)<0 and ω(α)>0, we have ω(α)=f(α)/ω(α)<0. Thus, the sign of ddα is opposite to the sign of ddω. By (3.11), we have

    ddω=d1π0costρ(ωcost)dt,d2dω2=d1π0cos2tρ(ωcost)dt,ddω(0)=ρ(0)d1π0costdt=0,d2dω2(0)=ρ(0)d1π0cos2tdt=ρ(0)d1π2. (3.12)

    After elementary calculations, we have

    f(u):=2mkγξumkξ(1+u)2u(1+u)3+k(1+u)3k(1+u)3;f(u):=2kmξ(γ+1+(12γ)u)2(1+u)4k(1+u)4,f(u):=6mξ((2γ1)u(1+2γ))(1+u)5.

    Since mξ>1 and k>1/(1+γ), we have f(0)=2mξ(γ+1)2k>0. Note that γ1/2 holds. Then, f(u)<0 for all u>0. Thus, f(u) is decreasing in (0,). Since f(0)>0, by f()=2/k and the properties of f(u), f(u)=0 has a unique root μ in (0,), such that f(u)>0 in (0,μ) and f(u)<0 in (μ,). We argue that f(μ)>0. Otherwise, since f(u) attains its maximum value at u=μ, we have f(u)0 for all u>0. Since f(0)=1mξ<0, we have f(u)<0. Since f(0)=0, thus f(u)<0, which is again impossible. Thus, f(μ)>0. By f(0)<0 and f()=, f(u)=0 has two roots μ1 and μ2 in (0,) with μ1<μ<μ2. In particular, 0<μ1<u1(ξ)<μ2<u2(ξ).

    Step 3: Since f(u1(ξ))=0, we have z(u1(ξ))=0. For u(0,μ1], we have f(u)<0,f(u)0,f(u)>0,F(u)F(u1(ξ))>0. Then, for u(0,μ1], we have z(u)<0. For u[μ2,u2(ξ)), we have f(u)>0,f(u)0,f(u)<0,F(u)F(u1(ξ))>0. Then, for u[μ1,u2(ξ)), we have z(u)<0. Next, we show that for u(μ1,μ2), z(u)<0. A straightforward calculation shows that,

    z(u)=2f(u)f(u)(F(u)F(u1(ξ)))+5f(u)(f2(u)2f(u)(F(u)F(u1(ξ)))),5f(u)z(u)3f(u)z(u)=2f(u)(F(u)F(u1(ξ)))z1(u), (3.13)

    where z1(u):=5(f(u))23f(u)f(u). For u(μ1,μ2), we have f(u)>0. By f(u)<0, we have z1(u)>0. On the other hand, by (3.9) and (3.13), we have ρ(0)=z1(u1(ξ))/(12f(u1(ξ))7)>0. This implies that for s close to zero, ρ(s)>0. Hence, by ρ(s)=ρ(s)z(u)/f4(u), for u close to u1(ξ), but not equal to u1(ξ), we have z(u)<0. As in [10], suppose for contradiction that there exists a ˆu(u1(ξ),μ2) such that z(ˆu)=0 and z(u)<0 for u(u1(ξ),ˆu), then z(ˆu)0 and f(ˆu)>0 and z1(ˆu)>0, which contradicts (3.13). Thus, z(u)<0 for all u(u1(ξ),u2(ξ)). Similarly, we can show that z(u)<0 for all u(0,u1(ξ)). Finally, by ρ(s)=ρ(s)z(u)/f4(u) and (3.12), for α(κ0(ξ),u1(ξ)), d/dα<0.

    So far, we are in the position to state our results on the existence of positive non-constant solutions of the shadow system:

    Theorem 3.3. Suppose that 14<γ12, f(λ)>d1π22 and k>11+γ hold, where λ is the first component of (λ,vλ). Then, the shadow system (3.2) admits at least one strictly increasing solution, and the same number of strictly decreasing solutions. The corresponding ξ satisfies ξ(ξ,ξ+), for some ξ,ξ+(0,p(u)).

    Proof. For ξ(1/m,p(u)), since ρ(0)=d1π/f(u1(ξ)), we have limαu1(ξ)(α)=ρ(0)=d1π/f(u1(ξ))=:0. Then, for <0, d1Δu+f(u)=0 has no non-constant solutions, while for >0 it does have. On the other hand, from the argument in the proof of Theorem 5 in [10], it follows that limακ0(ξ)(α)=+ and u is non-degenerate.

    As in the Step 3 of the proof of Lemma 3.2, we have shown that f(u1(ξ)) attains its unique maximal value (positive) at u1(ξ)=μ for some μ(μ1,μ2). Define =d1π/f(μ). Then, f(μ)=d1π2/2 and for any >, there have two numbers u<u+, such that δ(u,u+)(0,u) and f(u)=f(u+)=d1π2/2. Let ξ:=p(u) and ξ+:=p(u+). Then, for ξ(ξ,ξ+), we have f(u1(ξ))>d1π2/2; Thus, there must be a unique, increasing and non-degenerate solution u=u(x) to d1Δu+f(u)=0 subject to Neumann boundary conditions. Recall that under our assumptions, u1(ξ)=λ if and only if ξ=vλ. Then, if f(λ)>d1π2/2, we have f(μ)f(λ)>d1π2/2, which implies that > and ξ(ξ,ξ+). In particular, λ(u,u+). As , the set (ξ,ξ+) shrinks to an empty set, and as , (ξ,ξ+) expands to (1/m,p(u)). For fixed > and a given ξ(ξ,ξ+), we write

    α(ξ)=u(0),M(ξ):=10mu1+u(1γu1+u)dx. (3.14)

    It follows from the non-degeneracy of u that both α(ξ) and M(ξ) are continuous functions of ξ. If ξ(ξ,ξ+) is close to ξ, then u1(ξ) is close to u. Since =d1π/f(u), we know that α is close to u1(ξ) and then close to u too. Furthermore, the solution u(x) is nearly a constant. Then, by u<λ, M(ξ) is close to u and then we have M(ξ)<M(λ)=θ/m, where the integrant function in M(ξ) is increasing with respect to u when γ1/2. Similarly, for those ξ close to u+, by u+>λ, we have M(ξ)>M(λ)=θ/m. Then, by the continuity of M(ξ), there must have some ξ(ξ,ξ+) such that M(ξ)=θ/m.

    In this paper, we are mainly concerned with the existence of the spatial patterns of the diffusive system with plant-herbivore interactions with toxin-determined functional responses. By using the standard steady state bifurcation theorem, we are able to show that, for any fixed d1>0, if the diffusion rate d2 is larger than certain critical value, then the original non-degenerate system (both d1 and d2 are positive and finite) will have non-constant positive steady state solutions. Then, we continue to consider the limiting case when d2 tends to infinity. The corresponding limiting system is called the shadow system of the original system. By using the time-mapping methods, we have showed that the shadow system has non-constant positive steady state solutions under certain conditions. In the future, we shall concentrate ourselves on the dynamics of the predator-prey system with discontinuous reaction terms, which tends to be much more interesting than the current counterpart (see for example, [14,15]).

    The author would like to thank the reviewers for their kind suggestions and comments which significantly help improve the quality of the paper.

    The authors declare there is no conflicts of interest.

    [1] Howlader N, Noone A, Krapcho M, et al. (2015) SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD. 2015.
    [2] Tomasetti C, Li L, Vogelstein B (2017) Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355: 1330-1334. doi: 10.1126/science.aaf9011
    [3] Cancer Research UK, Statistics on preventable cancers. 2017. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/risk/preventable-cancers#heading-One
    [4] Colditz GA, Hankinson SE (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388-396. doi: 10.1038/nrc1608
    [5] Boeke CE, Eliassen AH, Chen WY, et al. (2014) Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies. Breast Cancer Res Treat 146: 383-392. doi: 10.1007/s10549-014-3005-8
    [6] Farvid MS, Cho E, Chen WY, et al. (2014) Premenopausal dietary fat in relation to pre- and post-menopausal breast cancer. Breast Cancer Res Treat 145: 255-265. doi: 10.1007/s10549-014-2895-9
    [7] Sasaki S, Horacsek M, Kesteloot H (1993) An ecological study of the relationship between dietary fat intake and breast cancer mortality. Prev Med 22: 187-202. doi: 10.1006/pmed.1993.1016
    [8] Chlebowski RT, Blackburn GL, Thomson CA, et al. (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98: 1767-1776. doi: 10.1093/jnci/djj494
    [9] Chlebowski RT (2013) Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 22 Suppl 2: S30-37.
    [10] Pierce JP, Natarajan L, Caan BJ, et al. (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298: 289-298. doi: 10.1001/jama.298.3.289
    [11] Sieri S, Chiodini P, Agnoli C, et al. (2014) Dietary fat intake and development of specific breast cancer subtypes. J Natl Cancer Inst 106.
    [12] Cao Y, Hou L, Wang W (2016) Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A meta-analysis of prospective cohort studies. Int J Cancer 138: 1894-1904. doi: 10.1002/ijc.29938
    [13] Bagga D, Anders KH, Wang HJ, et al. (2002) Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer 42: 180-185. doi: 10.1207/S15327914NC422_5
    [14] Murff HJ, Shu XO, Li H, et al. (2011) Dietary polyunsaturated fatty acids and breast cancer risk in Chinese women: a prospective cohort study. Int J Cancer 128: 1434-1441. doi: 10.1002/ijc.25703
    [15] Gago-Dominguez M, Yuan JM, Sun CL, et al. (2003) Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: The Singapore Chinese Health Study. Br J Cancer 89: 1686-1692. doi: 10.1038/sj.bjc.6601340
    [16] Khankari NK, Bradshaw PT, Steck SE, et al. (2015) Dietary intake of fish, polyunsaturated fatty acids, and survival after breast cancer: A population-based follow-up study on Long Island, New York. Cancer 121: 2244-2252. doi: 10.1002/cncr.29329
    [17] Wakai K, Tamakoshi K, Date C, et al. (2005) Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan. Cancer Sci 96: 590-599. doi: 10.1111/j.1349-7006.2005.00084.x
    [18] Kiyabu GY, Inoue M, Saito E, et al. (2015) Fish, n - 3 polyunsaturated fatty acids and n - 6 polyunsaturated fatty acids intake and breast cancer risk: The Japan Public Health Center-based prospective study. Int J Cancer 137: 2915-2926. doi: 10.1002/ijc.29672
    [19] Bagga D, Wang L, Farias-Eisner R, et al. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 100: 1751-1756. doi: 10.1073/pnas.0334211100
    [20] Chenais B, Blanckaert V (2012) The janus face of lipids in human breast cancer: how polyunsaturated Fatty acids affect tumor cell hallmarks. Int J Breast Cancer 2012: 712536.
    [21] Schwingshackl L, Hoffmann G (2016) Does a Mediterranean-Type Diet Reduce Cancer Risk? Curr Nutr Rep 5: 9-17. doi: 10.1007/s13668-015-0141-7
    [22] van den Brandt PA, Schulpen M (2017) Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis. Int J Cancer 140: 2220-2231. doi: 10.1002/ijc.30654
    [23] Pot GK, Stephen AM, Dahm CC, et al. (2014) Dietary patterns derived with multiple methods from food diaries and breast cancer risk in the UK Dietary Cohort Consortium. Eur J Clin Nutr 68: 1353-1358. doi: 10.1038/ejcn.2014.135
    [24] Toledo E, Salas-Salvado J, Donat-Vargas C, et al. (2015) Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial. JAMA Intern Med 175: 1752-1760. doi: 10.1001/jamainternmed.2015.4838
    [25] Farvid MS, Chen WY, Michels KB, et al. (2016) Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study. BMJ 353: i2343.
    [26] Liu Y, Colditz GA, Cotterchio M, et al. (2014) Adolescent dietary fiber, vegetable fat, vegetable protein, and nut intakes and breast cancer risk. Breast Cancer Res Treat 145: 461-470. doi: 10.1007/s10549-014-2953-3
    [27] Dam MK, Hvidtfeldt UA, Tjonneland A, et al. (2016) Five year change in alcohol intake and risk of breast cancer and coronary heart disease among postmenopausal women: prospective cohort study. BMJ 353: i2314.
    [28] Dong JY, Qin LQ (2011) Dietary glycemic index, glycemic load, and risk of breast cancer: meta-analysis of prospective cohort studies. Breast Cancer Res Treat 126: 287-294. doi: 10.1007/s10549-011-1343-3
    [29] Inoue-Choi M, Sinha R, Gierach GL, et al. (2016) Red and processed meat, nitrite, and heme iron intakes and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 138: 1609-1618. doi: 10.1002/ijc.29901
    [30] Touvier M, Fassier P, His M, et al. (2015) Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr 114: 347-357. doi: 10.1017/S000711451500183X
    [31] Tornberg SA, Holm LE, Carstensen JM (1988) Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 27: 31-37. doi: 10.3109/02841868809090315
    [32] Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Cancer Res 50: 2341-2346.
    [33] Furberg AS, Jasienska G, Bjurstam N, et al. (2005) Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 14: 33-40.
    [34] Ha M, Sung J, Song YM (2009) Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer Causes Control 20: 1055-1060. doi: 10.1007/s10552-009-9301-7
    [35] Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29: 1592-1598. doi: 10.1200/JCO.2010.31.5200
    [36] Li C, Yang L, Zhang D, et al. (2016) Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer. Nutr Res 36: 627-635. doi: 10.1016/j.nutres.2016.04.009
    [37] McDonnell DP, Park S, Goulet MT, et al. (2014) Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res 74: 4976-4982. doi: 10.1158/0008-5472.CAN-14-1756
    [38] Reeves GK, Pirie K, Beral V, et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335: 1134. doi: 10.1136/bmj.39367.495995.AE
    [39] Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15: 484-498. doi: 10.1038/nrc3967
    [40] Baumgartner KB, Hunt WC, Baumgartner RN, et al. (2004) Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women. Am J Epidemiol 160: 1087-1097. doi: 10.1093/aje/kwh313
    [41] Harris HR, Willett WC, Terry KL, et al. (2011) Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst 103: 273-278. doi: 10.1093/jnci/djq500
    [42] Jiralerspong S, Goodwin PJ (2016) Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. J Clin Oncol 34: 4203-4216. doi: 10.1200/JCO.2016.68.4480
    [43] Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, et al. (2014) Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. Breast Cancer Res Treat 146: 183-188. doi: 10.1007/s10549-014-2977-8
    [44] Printz C (2014) Obesity associated with higher mortality in women with ER-positive breast cancer. Cancer 120: 3267. doi: 10.1002/cncr.29079
    [45] Ottobelli Chielle E, de Souza WM, da Silva TP, et al. (2016) Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem 49: 548-553. doi: 10.1016/j.clinbiochem.2016.01.003
    [46] Bulun SE, Chen D, Moy I, et al. (2012) Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 23: 83-89. doi: 10.1016/j.tem.2011.10.003
    [47] Creighton CJ, Sada YH, Zhang Y, et al. (2012) A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat 132: 993-1000. doi: 10.1007/s10549-011-1595-y
    [48] Perks CM, Holly JM (2011) Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin North Am 40: 485-507, vii. doi: 10.1016/j.ecl.2011.05.010
    [49] Vadgama JV, Wu Y, Datta G, et al. (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330-340. doi: 10.1159/000012052
    [50] Kaaks R, Lundin E, Rinaldi S, et al. (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13: 307-316. doi: 10.1023/A:1015270324325
    [51] Sugumar A, Liu YC, Xia Q, et al. (2004) Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111: 293-297. doi: 10.1002/ijc.20253
    [52] Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13: 273-278. doi: 10.1677/erc.1.01219
    [53] Endogenous H, Breast Cancer Collaborative G, Key TJ, et al. (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11: 530-542. doi: 10.1016/S1470-2045(10)70095-4
    [54] Rinaldi S, Peeters PH, Berrino F, et al. (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593-605. doi: 10.1677/erc.1.01150
    [55] Allen NE, Roddam AW, Allen DS, et al. (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92: 1283-1287. doi: 10.1038/sj.bjc.6602471
    [56] Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, et al. (2005) Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 14: 48-52.
    [57] Schairer C, Hill D, Sturgeon SR, et al. (2004) Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-779. doi: 10.1002/ijc.11624
    [58] Signori C, DuBrock C, Richie JP, et al. (2012) Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr 66: 878-884. doi: 10.1038/ejcn.2012.60
    [59] Kabat GC, Kim M, Caan BJ, et al. (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125: 2704-2710. doi: 10.1002/ijc.24609
    [60] Goodwin PJ, Ennis M, Pritchard KI, et al. (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30: 164-171.
    [61] Sun W, Lu J, Wu S, et al. (2016) Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res 6: 2334-2344.
    [62] Lee JO, Kim N, Lee HJ, et al. (2016) Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep 6: 18923. doi: 10.1038/srep18923
    [63] Sun CA, Wu MH, Chu CH, et al. (2010) Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat 123: 869-876. doi: 10.1007/s10549-010-0792-4
    [64] Dalamaga M, Sotiropoulos G, Karmaniolas K, et al. (2013) Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem 46: 584-590.
    [65] Georgiou GP, Provatopoulou X, Kalogera E, et al. (2016) Serum resistin is inversely related to breast cancer risk in premenopausal women. Breast 29: 163-169. doi: 10.1016/j.breast.2016.07.025
    [66] Rahbar AR, Nabipour I (2014) The relationship between dietary lipids and serum visfatin and adiponectin levels in postmenopausal women. Endocr Metab Immune Disord Drug Targets 14: 84-92. doi: 10.2174/1871530314666140527143009
    [67] Dalamaga M, Karmaniolas K, Papadavid E, et al. (2011) Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 18: 1198-1204. doi: 10.1097/gme.0b013e31821e21f5
    [68] Lee YC, Yang YH, Su JH, et al. (2011) High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol Biomarkers Prev 20: 1892-1901. doi: 10.1158/1055-9965.EPI-11-0399
    [69] Kim SR, Park HJ, Bae YH, et al. (2012) Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology 153: 554-563. doi: 10.1210/en.2011-1413
    [70] Li C, Li J, Chen Y, et al. (2016) Effect of curcumin on visfatin and zinc-alpha2-glycoprotein in a rat model of non-alcoholic fatty liver disease. Acta Cir Bras 31: 706-713. doi: 10.1590/s0102-865020160110000001
    [71] Gao Y, Wang C, Pan T, et al. (2014) Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. Arq Bras Endocrinol Metabol 58: 42-47. doi: 10.1590/0004-2730000002840
    [72] Maffei M, Halaas J, Ravussin E, et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161. doi: 10.1038/nm1195-1155
    [73] Thompson HJ, Sedlacek SM, Wolfe P, et al. (2015) Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors. Nutrients 7: 5156-5176. doi: 10.3390/nu7075156
    [74] Alshaker H, Wang Q, Frampton AE, et al. (2015) Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Res Treat 149: 59-67. doi: 10.1007/s10549-014-3228-8
    [75] Park HS, Park JY, Yu R (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 69: 29-35. doi: 10.1016/j.diabres.2004.11.007
    [76] Bowers LW, Brenner AJ, Hursting SD, et al. (2015) Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production. Breast Cancer Res Treat 149: 49-57. doi: 10.1007/s10549-014-3223-0
    [77] Imayama I, Ulrich CM, Alfano CM, et al. (2012) Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 72: 2314-2326. doi: 10.1158/0008-5472.CAN-11-3092
    [78] Gao D, Rahbar R, Fish EN (2016) CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol 6.
    [79] Svensson S, Abrahamsson A, Rodriguez GV, et al. (2015) CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. Clin Cancer Res 21: 3794-3805. doi: 10.1158/1078-0432.CCR-15-0204
    [80] Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al. (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12: 4474-4480. doi: 10.1158/1078-0432.CCR-06-0074
    [81] D'Esposito V, Liguoro D, Ambrosio MR, et al. (2016) Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. Oncotarget 7: 24495-24509.
    [82] Li BH, He FP, Yang X, et al. (2017) Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res 180: 103-117 e104. doi: 10.1016/j.trsl.2016.08.006
    [83] Bell LN, Ward JL, Degawa-Yamauchi M, et al. (2006) Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab 291: E843-848. doi: 10.1152/ajpendo.00174.2006
    [84] Sundaram S, Freemerman AJ, Johnson AR, et al. (2013) Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat 142: 489-503. doi: 10.1007/s10549-013-2741-5
    [85] Ristimaki A, Sivula A, Lundin J, et al. (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635.
    [86] Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192. doi: 10.1054/bjoc.2000.1709
    [87] Brown KA, Simpson ER (2012) Obesity and breast cancer: mechanisms and therapeutic implications. Front Biosci (Elite Ed) 4: 2515-2524.
    [88] Davies NJ, Batehup L, Thomas R (2011) The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 105 Suppl 1: S52-73.
    [89] Cuzick J, Warwick J, Pinney E, et al. (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103: 744-752. doi: 10.1093/jnci/djr079
    [90] Kaaks R, Bellati C, Venturelli E, et al. (2003) Effects of dietary intervention on IGF-I and IGF-binding proteins, and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomised Trial. Eur J Clin Nutr 57: 1079-1088. doi: 10.1038/sj.ejcn.1601647
    [91] Wei M, Brandhorst S, Shelehchi M, et al. (2017) Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med 9.
    [92] Sandhu N, Schetter SE, Liao J, et al. (2016) Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial. Cancer Prev Res (Phila) 9: 275-282. doi: 10.1158/1940-6207.CAPR-15-0235
    [93] Sanderson M, Peltz G, Perez A, et al. (2010) Diabetes, physical activity and breast cancer among Hispanic women. Cancer Epidemiol 34: 556-561. doi: 10.1016/j.canep.2010.06.001
    [94] Irwin ML, Varma K, Alvarez-Reeves M, et al. (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev 18: 306-313. doi: 10.1158/1055-9965.EPI-08-0531
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6678) PDF downloads(1032) Cited by(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog